Toxicity as Biomarker for Response to Dose-Dense Sunitinib in mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Bjarnason GA, Naveen B, Winquist E, et al. Phase II Study of Individualized Sunitinib as First-Line Therapy for Metastatic Clear Cell Renal Cell Cancer (mRCC). Ann Oncol. 2014;25(Suppl 4):iv292.
- Rautiola J, Donskov F, Peltola K, et al. Sunitinib-induced hypertension, neutropenia and thrombocytopenia as predictors of good prognosis in metastatic renal cell carcinoma patients [published online ahead of print September 23, 2014]. BJU Int. doi: 10.1111/bju.12940.